文献速递脑血管病

左室收缩功能障碍无血栓卒中患者管理科学声明

Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association.
PubMed 文献 · Stroke · 2026-07-02

美国心脏协会科学声明总结左室收缩功能障碍(LVEF≤40%或左室壁运动异常)无血栓患者卒中风险及管理证据。Meta分析显示抗凝对一级预防无净获益,对卒中后二级预防可能优于抗血小板,推荐个体化共享决策及心脑多学科协作。

要点

  • 左室收缩功能障碍无血栓患者抗凝用于一级预防无净获益。
  • 卒中后抗凝可能降低复发风险且净获益优于抗血小板。
  • 治疗决策需个体化、共享决策及心脑多学科协作。

核心结论

  • 左室收缩功能障碍无血栓患者抗凝对一级预防无净获益,但卒中后抗凝可能优于抗血小板。

研究设计与样本

  • 美国心脏协会科学声明,对评估抗凝与非抗凝策略的随机临床试验二次分析进行叙述性总结与Meta分析。

主要发现

  • 左室收缩功能障碍无血栓患者抗凝与较低的新发卒中风险相关,但一级预防无净获益。
  • 卒中伴左室收缩功能障碍患者抗凝可能降低复发卒中风险,较抗血小板治疗有净获益。

临床怎么用

  • 抗凝决策需个体化,医患共享决策讨论风险获益。
  • 心内科与神经科多学科协作优化心脑健康。

局限性

  • 支持抗凝的数据有限,证据主要来自随机临床试验二次分析的Meta分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Left ventricular (LV) systolic dysfunction, defined here as reduced LV ejection fraction ≤40% or left wall motion abnormality, is commonly found in patients with ischemic stroke. Although there is an increased risk of incident and recurrent embolic stroke among patients with LV dysfunction without thrombus detected, the data supporting anticoagulation in these patients are limited. In this scientific statement, we summarize the latest evidence regarding the risk of incident and recurrent stroke in patients with LV dysfunction as well as best practice recommendations regarding the management of this population after stroke. We provide a narrative summary and meta-analysis of secondary analyses of randomized clinical trials that evaluated outcomes following anticoagulation versus nonanticoagulation strategies. Whereas anticoagulation is associated with a lower risk of incident stroke in patients with LV dysfunction without thrombus, there remains no net benefit of this strategy over a nonanticoagulant strategy for primary stroke prevention. For patients with stroke and LV dysfunction, anticoagulation may be associated with a lower risk of recurrent stroke and a net benefit when compared with antiplatelet therapy. Anticoagulation treatment decisions in these patients may involve individualized consideration, shared decision-making between patients and healthcare professionals upon discussing risks and benefits, and multidisciplinary collaboration between cardiology and neurology clinicians to optimize cardiac and brain health. As a key modifiable stroke risk factor and therapeutic target, LV dysfunction represents a target for future research.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Sharma R, Levine GN, Spinler SA, et al. Management of Patients at Risk of Ischemic Stroke With Left Ventricular Systolic Dysfunction in the Absence of Intracardiac Thrombus: A Scientific Statement From the American Heart Association. Stroke. 2026. PMID: 42389837. doi:10.1161/STR.0000000000000528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。